Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer

Fig. 4

a HER2-staining by IHC in the gastric cancer cell lines (i) ESO26, (ii) NCI-N87, (iii) OE19, (iv) SNU16 and (v) KATOIII. Images i, ii and iii were taken at 10X magnification, while images iv, and v were taken at 20X magnification. b Western blot analysis of expression of p-AKT, AKT, p-P70S6K (T389), P70S6K, MAPK ERK 1/2 (T202/Y204), MAPK ERK 1/2, PI3K P110α, and β-actin in the gastric cancer cell lines NCI-N87, ESO26, OE19, KATOIII and SNU16. All gels were run under the same experimental conditions and the experiments were repeated three times. Representative images are shown

Back to article page